A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)
A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autonoma Buenos Aires, C1055AAF, Argentina
Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
Curtiba, Paraná 80030-110, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
Culiacán, Sinaloa 80000, Mexico
Krasnoyarsk, Krasnoyarsk Krai 660062, Russia
Moscow, Moscow Oblast 115522, Russia
Moscow, Moscow Oblast 119049, Russia
Moscow, Moscow Oblast 119992, Russia
Yekaterinburg, Sankt-Peterburg 620043, Russia
Yaroslavl, Volgograd Oblast 150051, Russia
Saratov, 410026, Russia
Daejeon, 35015, South Korea
Ivano-Frankivsk, KIEV Governorate 76008, Ukraine
Lviv, KIEV Governorate 79010, Ukraine
Lviv, KIEV Governorate 79014, Ukraine
Dnipro, Tavria Okruha 49008, Ukraine
Zaporizhzhya, 69096, Ukraine